BeiGene (BGNE) Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma

Go back to BeiGene (BGNE) Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
(NASDAQ: BGNE) Delayed: 311.97 -2.03 (0.65%)
Previous Close $314.00    52 Week High $36.76 
Open $321.09    52 Week Low $22.51 
Day High $327.39    P/E N/A 
Day Low $309.53    EPS $0.00 
Volume 304,112